DURATA THERAPEUTICS
Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners. Durata is focused on Vicuron’s antibiotic drug candidate, dalbavancin. Its product portfolio also includes two preclinical antibiotic programs while Pfizer will retain the marketed anti-fungal agent, EraxisTM, which was formerly owned by Vicuron.
DURATA THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2009-01-01
Address:
Branford, Connecticut, United States
Country:
United States
Website Url:
http://www.duratatherapeutics.com
Total Employee:
51+
Status:
Closed
Contact:
312-219-7000
Email Addresses:
[email protected]
Total Funding:
70 M USD
Technology used in webpage:
SPF Amazon Microsoft Azure DNS Amazon Virginia Region ASP.NET Ajax Amazon Sydney Region Cisco Ironport Cloud MarkMonitor DNS Xand
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-12-21 | Vicuron Pharmaceuticals | Vicuron Pharmaceuticals acquired by Durata Therapeutics | N/A |
Investors List
PDL Biopharma
PDL Biopharma investment in Post-IPO Equity - Durata Therapeutics
Official Site Inspections
http://www.duratatherapeutics.com
Unable to get host informations!!!
More informations about "Durata Therapeutics"
Durata Therapeutics - Wikipedia
Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million. See details»
Durata Therapeutics - Crunchbase Company Profile & Funding
Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock …See details»
Durata Therapeutics 2025 Company Profile: Valuation, Investors ...
Durata Therapeutics General Information Description. Developer of pharmaceutical treatments for infectious disease and acute illnesses. The company develops and commercializes Dalvance, …See details»
Durata Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Durata Therapeutics, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
Durata Therapeutics - Ownership and Business Overview - Mergr
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute …See details»
Durata Therapeutics Company Profile | Management and
Durata Therapeutics Profile and History. Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of new therapeutics for patients with …See details»
Durata Therapeutics - Company Profile - Tracxn
Feb 12, 2025 Durata Therapeutics is clinical development stage pharmaceutical company with a focus on treating infectious diseases. The firm was in the process of developing a novel …See details»
Durata Therapeutics - VentureRadar
Durata Therapeutics Follow Following Location: USA. Founded in 2009. Develops novel antibiotic programs through late-stage clinical trials as a biopharmaceutical company focused on …See details»
Organization | Durata
Organization Overview. First Clinical Trial. 2013 NCT01946568. First Marketed Drug. 2014 dalbavancin . First NDA Approval. 2014 dalbavancin ... Durata Therapeutics Active …See details»
Durata Therapeutics - Products, Competitors, Financials, …
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. …See details»
Durata Therapeutics: Contact Details and Business Profile
Durata Therapeutics Inc. established in 2009, is a clinical development stage biopharmaceutical company addressing the growing need for new therapeutics to treat infectious diseases. …See details»
Durata Therapeutics - EquityNet
Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock …See details»
Durata Therapeutics U.S. Limited - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Durata Therapeutics U.S. Limited of Chicago, IL. Get the latest business insights from Dun & Bradstreet.See details»
Durata Therapeutics - Contacts, Employees, Board Members
Durata Therapeutics is a clinical, development-stage pharmaceutical company focused on the treatment of infectious diseases. ... Experience the new Crunchbase, powered by AI . …See details»
Actavis to Acquire Durata Therapeutics, Inc. | Fierce Pharma
Oct 6, 2014 DUBLIN, Ireland and CHICAGO, Oct. 6, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Durata Therapeutics, Inc. …See details»
Durata Therapeutics Relocating Corporate Headquarters to Chicago
Nov 14, 2012 Durata Therapeutics Relocating Corporate Headquarters to Chicago MORRISTOWN, N.J & CHICAGO--(BUSINESS WIRE) ... The Biotechnology Industry …See details»
Actavis to buy Durata in a deal valued at about $675 million
Oct 6, 2014 Generic drugmaker Actavis Plc <ACT.N> said it would acquire Durata Therapeutics Inc <DRTX.O> in a deal valued at about $675 million to bolster its infectious …See details»
Durata Therapeutics, Inc. (Durata Therapeutics, Inc.) - 药物管线_专 …
了解Durata Therapeutics, Inc. (Durata Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的7项临床试验, 9篇新闻和5篇文献，药物:盐酸达巴万星。 ... Together, we have …See details»
Durata Therapeutics-动脉网 - vbdata.cn
Durata Therapeutics是一家专注于治疗传染病的临床、研发阶段的制药公司。Durata是由一个由五名成员组成的风险投资财团创建的，该财团致力于新型抗生素项目的后期临床开发。See details»